Source:http://linkedlifedata.com/resource/pubmed/id/16369750
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2005-12-21
|
| pubmed:abstractText |
Sarcomas represent a rare and heterogeneous disease and the prognosis of patients remains poor, with a disease-free survival at 5 years of less than 10%. Only a few chemotherapeutic agents, such as doxorubicin and ifosfamide, have been identified to be active with response rates above 20%. The concept of angiostatic therapy in combination with proapoptotic biomodulators and chemotherapeutics has not been evaluated in these patients. Therefore, the efficacy of low-dose trofosfamide in combination with the peroxisome proliferator-activated receptor-gamma-agonist, pioglitazone, and the selective cyclooxygenase-2 inhibitor, rofecoxib, was evaluated in a pilot study. Six patients with advanced sarcoma received a combination of oral pioglitazone plus rofecoxib and, after 14 days, oral trofosfamide. The therapy was administered continuously daily. Four patients received the triple combination as maintenance therapy; three of them achieved stabilization of disease. Two patients received the combination as relapse therapy; however, it failed to stop disease progression. Side effects were generally mild and hospitalization was not necessary. This new triple combination of low-dose trofosfamide, pioglitazone, and rofecoxib may represent a feasible new alternative in the palliative treatment of sarcoma patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Lactones,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfones,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazolidinediones,
http://linkedlifedata.com/resource/pubmed/chemical/pioglitazone,
http://linkedlifedata.com/resource/pubmed/chemical/rofecoxib,
http://linkedlifedata.com/resource/pubmed/chemical/trofosfamide
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1341-9625
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
438-40
|
| pubmed:meshHeading |
pubmed-meshheading:16369750-Adult,
pubmed-meshheading:16369750-Angiogenesis Inhibitors,
pubmed-meshheading:16369750-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16369750-Bone Neoplasms,
pubmed-meshheading:16369750-Cyclophosphamide,
pubmed-meshheading:16369750-Female,
pubmed-meshheading:16369750-Humans,
pubmed-meshheading:16369750-Lactones,
pubmed-meshheading:16369750-Male,
pubmed-meshheading:16369750-Middle Aged,
pubmed-meshheading:16369750-Neovascularization, Pathologic,
pubmed-meshheading:16369750-Palliative Care,
pubmed-meshheading:16369750-Pilot Projects,
pubmed-meshheading:16369750-Sarcoma,
pubmed-meshheading:16369750-Soft Tissue Neoplasms,
pubmed-meshheading:16369750-Sulfones,
pubmed-meshheading:16369750-Thiazolidinediones,
pubmed-meshheading:16369750-Treatment Outcome
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
A new therapeutic approach in patients with advanced sarcoma.
|
| pubmed:affiliation |
University of Heidelberg, Department of Internal Medicine V, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany. Bernd.Kasper@med.uni-heidelberg.de
|
| pubmed:publicationType |
Journal Article,
Case Reports
|